Dual therapy with etravirine plus raltegravir for virologically suppressed HIV-infected patients: a pilot study

The CD4/CD8 ratio as a marker T-cell activation, senescence and activation/exhaustion in treated HIV-infected children and young adults

(2013) Talía Sainz et al.   AIDS

Lipid-Lowering Effect and Efficacy After Switching to Etravirine in HIV-Infected Patients With Intolerance to Suppressive HAART

(2013) José L. Casado et al.   HIV CLINICAL TRIALS

Association Between Antiretroviral Exposure and Renal Impairment Among HIV-Positive Persons With Normal Baseline Renal Function: the D:A:D Studya

(2013) L. Ryom et al.   JOURNAL OF INFECTIOUS DISEASES

Dual raltegravir/etravirine combination in virologically suppressed HIV-1-infected patients on antiretroviral therapy

(2012) Ruxandra Calin et al.   ANTIVIRAL THERAPY

Acceptable Plasma Concentrations of Raltegravir and Etravirine When Administered by Gastrostomy Tube in a Patient with Advanced Multidrug-Resistant Human Immunodeficiency Virus Infection

(2012) Uriel Sandkovsky et al.   PHARMACOTHERAPY

Raltegravir dosage adjustment in HIV-infected patients receiving etravirine

(2011) V. T. Do et al.   AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY

Premature Age-Related Comorbidities Among HIV-Infected Persons Compared With the General Population

(2011) G. Guaraldi et al.   CLINICAL INFECTIOUS DISEASES

Trends in virological and clinical outcomes in individuals with HIV-1 infection and virological failure of drugs from three antiretroviral drug classes: a cohort study

(2011)   LANCET INFECTIOUS DISEASES

Substitution of raltegravir for ritonavir-boosted protease inhibitors in HIV-infected patients: the SPIRAL study

(2010) Esteban Martinez et al.   AIDS

Resistance profile of etravirine: combined analysis of baseline genotypic and phenotypic data from the randomized, controlled Phase III clinical studies

(2010) Johan Vingerhoets et al.   AIDS

Characterization of Genotypic and Phenotypic Changes in HIV-1-Infected Patients with Virologic Failure on an Etravirine-Containing Regimen in the DUET-1 and DUET-2 Clinical Studies

(2010) Lotke Tambuyzer et al.   AIDS RESEARCH AND HUMAN RETROVIRUSES

Prevalence of comedications and effect of potential drug–drug interactions in the Swiss HIV Cohort Study

(2010) Catia Marzolini et al.   ANTIVIRAL THERAPY

Efficacy and safety of etravirine at week 96 in treatment-experienced HIV type-1-infected patients in the DUET-1 and DUET-2 trials

(2010) Christine Katlama et al.   ANTIVIRAL THERAPY

Switch to a raltegravir-based regimen versus continuation of a lopinavir-ritonavir-based regimen in stable HIV-infected patients with suppressed viraemia (SWITCHMRK 1 and 2): two multicentre, double-blind, randomised controlled trials

(2010) Joseph J Eron et al.   LANCET

Comparison of genotypic resistance profiles and virological response between patients starting nevirapine and efavirenz in EuroSIDA

(2009) Wendy P Bannister et al.   AIDS

Etravirine–raltegravir, a marked interaction in HIV-1-infected patients: about four cases

(2009) Amélie Ménard et al.   AIDS

Minority Variants Associated with Transmitted and Acquired HIV-1 Nonnucleoside Reverse Transcriptase Inhibitor Resistance: Implications for the Use of Second-Generation Nonnucleoside Reverse Transcriptase Inhibitors

(2009) Vici Varghese et al.   JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES

Risk of Myocardial Infarction in Patients with HIV Infection Exposed to Specific Individual Antiretroviral Drugs from the 3 Major Drug Classes: The Data Collection on Adverse Events of Anti‐HIV Drugs (D:A:D) Study

(2009) Signe Westring Worm et al.   JOURNAL OF INFECTIOUS DISEASES

Minimal Pharmacokinetic Interaction between the Human Immunodeficiency Virus Nonnucleoside Reverse Transcriptase Inhibitor Etravirine and the Integrase Inhibitor Raltegravir in Healthy Subjects

(2008) M. S. Anderson et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Quantification of the HIV-integrase inhibitor raltegravir (MK-0518) in human plasma by high-performance liquid chromatography with fluorescence detection

(2008) Jean-Marie Poirier et al.   JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES

Raltegravir with Optimized Background Therapy for Resistant HIV-1 Infection

(2008) Roy T. Steigbigel et al.   NEW ENGLAND JOURNAL OF MEDICINE